Ivabradine is a prototype of a new class of If-channel inhibitors (special ion channels for stimuli conduction). In this case, a slowing of the pulse is achieved without influencing the conduction system, the cardiac muscle force and the blood pressure. Therefore, Ivabradine can be used in angina pectoris, which is not treatable with β-blockers. If the heart rate is too high, it can also be used in combination with β-blockers. 2012 the approval for the treatment of chronic heart failure was given.